Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients. Yannis Morel will present in the Showcase Session 2 on Thursday, April 16, 2026, at 6:10 PM PDT, at the San Diego Convention Center in San Diego, California.
The AACR Oncology Industry Partnering Event is an annual forum that brings together venture capitalists, investment bankers, biotech and pharmaceutical scientific and business leaders focused on oncology drug development and entrepreneurship. The showcase sessions provide selected biotechnology companies the opportunity to highlight their oncology pipelines, platforms, and strategies for innovation directly to an audience of analysts and investors.
“We are delighted to have been selected to present at the AACR Oncology Industry Partnering Event, which is a unique forum bringing together biotech, pharma and investors. Innate Pharma’s selection to present during this forum is a recognition of our exciting clinical pipeline and provides a valuable opportunity to share the progress of our key assets including IPH4502 our Nectin-4 ADC. We look forward to the conversations that these interactions can spark and their potential to accelerate the development of our differentiated therapies for patients,” said Yannis Morel, Chief Operating Officer of Innate Pharma.
Presentation Details
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Session: Showcase Session 2, Meeting Room 11
Date/Time: Thursday, April 16, 2026, 6:10 PM PDT
Presenter: Yannis Morel, Chief Operating Officer, Innate Pharma
Location: San Diego Convention Center, San Diego, California
| Press Release in English | 237.45 KB |
| 260408 Innate OIPE AACR 2026 French.pdf | 199.62 KB |